Asan Medical Center
Seoul, 138-736, South Korea
NCT Number: NCT01378650
1. Overview of tinnitus Tinnitus is a noisy sound which is perceived without any external sound source. According to the survey of the US, 10-20% of adult have the symptom of tinnitus and 3-5% of tinnitus patients have severe discomfort of daily life. Severe tinnitus can result in psychiatric problems such as depression and anxiety disorders. Enhancement of environmental sound, hearing aids, sound generators, cognitive therapy, transcranial magnetic therapy, and drug therapy have been tried for treatment of tinnitus. Nitric oxide(NO) is a well-known neurotransmitter acting as a vasodilator through regulation of production of cyclic guanosine monophosphate(cGMP) and can be found in various sites of cochlea. It is reported that cGMP enhances activity of protein kinase A (PKA), a mediator of platelet aggregation inhibition and vasodilatation and results in increase of vascular flow. 2. Characteristics of the clinical research drug, cilostazol Cilostazol inhibits phosphodiesterase type 3 (PDE3) selectively and increases amount of cAMP by inhibition of degradation of cyclic adenosine monophosphate(cAMP). cAMP again by increasing the active form of PKA suppress the production of blood clots and increase blood flow by expanding blood vessels. Anti-platelet activity and vasodilatation effect of cilostazol have been used for improvement of diabetic peripheral vascular disorders and suppression of stroke recurrence. Previous studies reported that by increasing the activity of NO and PKA, the blood flow of stria vascularis and cochlear hair cells can be improved. These studies implies that cilostazol, which causes inhibition of PDE3 and increase of PKA, can have a potential effect on improvement of tinnitus by increase of blood flow to peripheral cochlear cells. Thus, we hypothesized that cilostazol, which has been widely used for enhancing peripheral blood flow, can bring improvement of tinnitus by causing better peripheral blood flow of cochlea. 3. The aim of the study We planned this study to validate the assumptions of the background. The aim of our study is whether administration of cilostazol can improve tinnitus in terms of subjective degree of symptoms in chronic tinnitus patients.
Looking for future studies?
Notify Me20 year and older
All sexes
Interventional
Not applicable
Seoul, 138-736, South Korea
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Administration of Cilostazol 100mg twice a day for 4 weeks
Other names: Pletaal
placebo one tablet matching for cilostazol twice a day for 4 weeks.
Other names: Placebo matching for cilostazol
Time frame: within 2 weeks before administration, 2 weeks after administration, 4 week after administration
A Questionnaire for assessing subjective discomfort from chronic tinnitus
Time frame: within 2weeks before administration, 2 weeks after administration, 4 weeks after administration
A questionnaire for assessing subjective discomfort from chronic tinnitus
Time frame: within 2 weeks before administration, 2 weeks after administration, 4 week after administration
A Questionnaire for assessing subjective discomfort from chronic tinnitus
Jong Woo Chung
Other
A Randomized, Prospective, Placebo-controlled Double-blind, Pilot Study on the Effect of Cilostazol for 4 Weeks in Patients With Chronic Tinnitus
Acronym: CITI-ESR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07731230
Ear Diseases, Hearing Disorders
Istanbul, Kadikoy, Turkey (Türkiye)
View Trial DetailsNCT04661995
Ear Diseases, Hearing Disorders
Durham, North Carolina, United States
View Trial DetailsNCT07637708
Ear Diseases, Hearing Disorders
Santiago, Chile
View Trial DetailsNCT07631403
Ear Diseases, Hearing Disorders
Ankara, Turkey (Türkiye)
View Trial Details